Arrowhead Pharmaceuticals, Inc.

138 patents currently held · Updated Nov 15, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Previously recorded as Arrowhead Research Corporation (to 2017)

Ending by 2030

Dec 2026

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

3 fees due Dec 4 to 25, 2026 · next Dec 4
2 fees due Jan 7 to 14, 2027 · next Jan 7
3 fees due Feb 4 to 25, 2027 · next Feb 4
2 fees due Mar 15 to 22, 2027 · next Mar 15
1 fee due Apr 22, 2027
The maintenance fee for Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use (US 10,450,565) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
1 fee due May 3, 2027
The maintenance fee for RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS (US 9,173,896) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
2 fees due Jun 12 to 19, 2027 · next Jun 12
4 fees due Jul 12 to 30, 2027 · next Jul 12
3 fees due Aug 2 to 27, 2027 · next Aug 2
4 fees due Sep 5 to 24, 2027 · next Sep 5
1 fee due Oct 14, 2027
The maintenance fee for Compositions and Methods for Inhibiting Expression of RRM2 Genes (US 10,619,160) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 17, 2026
4 terms have ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,981,870	Rnai-Mediated Inhibition of H1F1A for Treatment of Ocular Angiogenesis In force Term ends Dec 19, 2026 · Medium confidence	In force	Term ends Dec 19, 2026	Medium confidence
US 8,940,887	RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS In force Term ends Dec 19, 2026 · Medium confidence	In force	Term ends Dec 19, 2026	Medium confidence
US 9,765,340	Rnai-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of Camp-Related Ocular Disorders In force Term ends Dec 28, 2026 · Medium confidence	In force	Term ends Dec 28, 2026	Medium confidence
US 9,453,220	RNAi-MEDIATED INHIBITION OF PHOSPHODIESTERASE TYPE 4 FOR TREATMENT OF cAMP-RELATED OCULAR DISORDERS In force Term ends Feb 4, 2027 · Medium confidence	In force	Term ends Feb 4, 2027	Medium confidence
US 7,947,660	Rnai-Mediated Inhibition of Frizzled Related PROTEIN-1 for Treatment of Glaucoma In force Term ends Mar 31, 2027 · High confidence	In force	Term ends Mar 31, 2027	High confidence
US 8,222,227	Rnai-Mediated Inhibition of Histamine Receptor H1-RELATED Conditions In force Term ends Apr 10, 2027 · High confidence	In force	Term ends Apr 10, 2027	High confidence
US 9,206,428	RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions In force Term ends Apr 10, 2027 · High confidence	In force	Term ends Apr 10, 2027	High confidence
US 9,745,585	Rnai-Mediated Inhibition of Histamine Receptor H1-RELATED Conditions In force Term ends Apr 10, 2027 · High confidence	In force	Term ends Apr 10, 2027	High confidence
US 9,371,529	RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS In force Term ends Apr 13, 2027 · High confidence	In force	Term ends Apr 13, 2027	High confidence
US 9,447,419	RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS In force Term ends May 17, 2027 · Medium confidence	In force	Term ends May 17, 2027	Medium confidence

10 of 138 patents shown.

Pro members see all 138.

Pro members: see all 138 patents

Also on record, not counted in the 138: 1 patent in force now held by others · 24 lapsed for an unpaid fee · 9 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

23 pending · 23 abandoned · 23 no status recorded

List them